Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

HAEMATOLOGICAL CANCER

KTE-X19 active in MCL

Nature Reviews Clinical Oncology volume 17, page 336 (2020)Cite this article

Subjects

The survival outcomes of patients with relapsed and/or refractory mantle-cell lymphoma (MCL) after receiving BTK inhibitors are poor; therefore, new treatment options are needed for these patients. Chimeric antigen receptor (CAR) T cell therapies targeting CD19 have demonstrated efficacy in several subtypes of B cell lymphomas, although limited results in patients with MCL have been reported. Now data from the ZUMA-2 trial reveal promising activity of the anti-CD19 CAR T cell product KTE-X19 against MCL.

In ZUMA-2, KTE-X19 was successfully manufactured for 71 of 74 patients with relapsed and/or refractory MCL. A high content of leukaemic blasts in peripheral blood has been proposed as the cause of failed manufacturing of CAR T cells because it results in proportionally low numbers of non-exhausted T cells in the starting cell population. During the manufacturing of KTE-X19, circulating CD19+ malignant cells were removed in order to address this issue by reducing the potential activation and exhaustion of anti-CD19 CAR T cells in the ex vivo portion of the process.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

Original article

  • Wang, M. et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 383, 1331–1342 (2020)

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Clinical Oncology http://www.nature.com/nrclinonc

    Diana Romero

Authors
  1. Diana Romero
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Diana Romero.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Romero, D. KTE-X19 active in MCL. Nat Rev Clin Oncol 17, 336 (2020). https://doi.org/10.1038/s41571-020-0373-3

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41571-020-0373-3

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing